Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
302 stopped studies mapped to Invasive Carcinoma and descendants · 92% state a reason
Over the 302 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | Phase 1 | withdrawn | Jan 22, 2024 | University of California, San Diego | closed early due to low (0) accrual | Enrollment / accrual |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT02876640 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | Phase 1 | terminated | Aug 24, 2016 | National Cancer Institute (NCI) | Inadequate Accrual Rate | Enrollment / accrual |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | N/A | withdrawn | Sep 28, 2023 | The University of Tennessee, Knoxville | Unable to recruit participants | Enrollment / accrual |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Phase 1 | terminated | Nov 4, 2021 | Nurix Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma… | Phase 1 / Phase 2 | terminated | Sep 14, 2022 | Avenge Bio, Inc | Sponsor Decision to close study | Sponsor / business decision |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in… | Phase 1 / Phase 2 | terminated | Oct 17, 2017 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate development of the program. | Sponsor / business decision |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | Phase 1 / Phase 2 | terminated | Apr 29, 2009 | University Health Network, Toronto | Poor recruitment | Enrollment / accrual |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or… | Phase 1 / Phase 2 | terminated | Oct 16, 2013 | Fox Chase Cancer Center | Study drug is no longer supplied by grantor. | Other (stated, no rule matched) |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage… | Early Phase 1 | terminated | Dec 5, 2017 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn. | Funding |
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | Phase 1 | terminated | Jan 31, 2022 | Lioe-Fee de Geus-Oei, MD PhD | Reached the stop criteria after the interim analysis | Efficacy / futility |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With… | Phase 2 | terminated | Oct 5, 2016 | M.D. Anderson Cancer Center | The study was terminated early by the Sponsor | Other (stated, no rule matched) |
| NCT04718376 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed… | Phase 1 | terminated | Jan 22, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic… | Phase 2 | terminated | Mar 5, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate…(HIIT PCa) | N/A | withdrawn | Dec 14, 2021 | The University of Texas Health Science Center at San Antonio | PI left the institution, no subjects were enrolled | Investigator |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT03970967 | Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma… | N/A | terminated | Jun 3, 2019 | Alpha Tau Medical LTD. | Difficulty in recruiting patients | Enrollment / accrual |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | N/A | terminated | Jul 30, 2018 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT04999605 | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Akeso | Too low inclusion rate | Other (stated, no rule matched) |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of… | — | withdrawn | Apr 11, 2018 | HKGepitherapeutics | No participants enrolled, leading to insufficient patient numbers to initiate the clinical trial. | Enrollment / accrual |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer… | N/A | terminated | Aug 22, 2018 | University of Washington | Enrollment ended early due to the funding timeline | Enrollment / accrual |
| NCT03412630 | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With… | N/A | terminated | Jan 26, 2018 | ECOG-ACRIN Cancer Research Group | poor accrual | Enrollment / accrual |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT02834975 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial… | Phase 2 | terminated | Jul 15, 2016 | University of Miami | Investigator left institution | Investigator |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous… | Phase 3 | terminated | May 9, 2013 | Pfizer | Per recommendation of the DMC, enrollment into the study was discontinued in April 2016 after the… | Efficacy / futility |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With…(AXLerate-OC) | Phase 3 | terminated | Jan 28, 2021 | Aravive, Inc. | There were no significant differences in median PFS between batiraxcept + paclitaxel or paclitaxel… | Safety / toxicity |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron… | Phase 2 | terminated | Aug 28, 2018 | University of Washington | Terminated due to low accrual. | Enrollment / accrual |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | Phase 3 | terminated | Apr 15, 2022 | Mersana Therapeutics | Study Terminated by Sponsor | Other (stated, no rule matched) |
| NCT04907968 | Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With…(UPGRADE) | Phase 1 | terminated | Jun 1, 2021 | Mersana Therapeutics | Study Terminated by Sponsor | Other (stated, no rule matched) |
| NCT06069453 | Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC. | N/A | terminated | Oct 5, 2023 | Fidia Farmaceutici s.p.a. | Sponsor decision | Sponsor / business decision |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | Phase 1 | terminated | Oct 25, 2019 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double… | Phase 2 | terminated | Jun 26, 2019 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and… | Phase 2 | withdrawn | Mar 25, 2022 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 25, 2010 | University of Nebraska | study sponsors withdrew support for the study drug. | Other (stated, no rule matched) |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant… | Phase 2 | terminated | Apr 11, 2019 | Stanford University | Difficulty with enrollment | Enrollment / accrual |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating… | Phase 1 | terminated | Dec 4, 2019 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT00968799 | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A… | N/A | terminated | Aug 31, 2009 | Cantonal Hospital of St. Gallen | poor patient accrual | Enrollment / accrual |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT04901299 | Fulvestrant + Neratinib In Breast Cancer(HER2-Signal) | Phase 2 | withdrawn | May 25, 2021 | Massachusetts General Hospital | Team decision | Other (stated, no rule matched) |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | withdrawn | Mar 4, 2021 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined…(THRIP) | N/A | terminated | Jun 12, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | outdated, progress in clinical practice. | Other (stated, no rule matched) |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | Phase 3 | terminated | May 24, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by DSMB due to futility. | Efficacy / futility |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | Phase 1 / Phase 2 | terminated | Apr 13, 2021 | Veru Inc. | Study terminated as end points were not achieved at current dose level. | Other (stated, no rule matched) |
| NCT04088435 | Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer | — | terminated | Sep 12, 2019 | University of Louisville | Low accrual | Enrollment / accrual |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent… | Phase 2 | withdrawn | Feb 21, 2023 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Program changed | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 20, 2024source: clinicaltrials